FIELD: medicine, pharmacology. SUBSTANCE: invention proposes a novel agent for inhibition of apoptosis in cell population of T-lymphocytes. An agent is an agonist showing the specificity to receptors of retinoic acid RAR-alpha (in part, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2- naphthalinyl)carboxamido] - -benzoic acid), or 4-[7-(1-adamantyl)-6-methoxyethoxymethoxy-2- naphthyl] benzoic acid. An agent is designated for treatment of diseases associated with the excessive apoptosis rate, among them, immunodeficiency syndrome induced by human immunodeficiency virus (HIV) or a graft rejection. EFFECT: expanded arsenal of agents of designation claimed. 5 cl, 4 tbl
